All In Biotech

Drug Trial Radar · NCT00520806

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure

Last checked: Nov 20, 2026Latest source record: Oct 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,161

Actual

Start

Oct 2007

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

Conditions

  • Heart Failure, Congestive

Interventions

  • RelaxinDrug

    Intravenous infusion for 48 h at 30 ug/kg/day

  • PlaceboDrug

    Intravenous infusion for 48 h

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relief of dyspnea in acute heart failureTime frame: Up to day 5

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois

  • Wayne State University/Detroit Receiving Hospital

    Detroit, Michigan

  • Heart Institute

    Safed, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.